{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:38:49Z","timestamp":1765262329163,"version":"3.46.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy for metastatic colorectal cancer (mCRC) leads to varying patient outcomes owing to the heterogeneity of metastatic organs. However, whether the metastatic organ count influences prognosis in mCRC patients receiving immunotherapy remains unclear. Therefore, this retrospective study aimed to investigate this issue to derive a clear conclusion to facilitate clinical treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 208 patients with mCRC receiving immunotherapy at the Sun Yat-sen University Cancer Center. Cox regression analysis was conducted to determine variables independently associated with immunotherapy response and progression-free survival (PFS). The Kaplan\u2013Meier curve analysis and log-rank test were used to evaluate PFS across varying metastatic organ counts. Subsequently, a nomogram was constructed for PFS prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with varying metastatic organ counts exhibited significantly different objective response rates (ORRs) (1 to \u22654 organs: 49.3%, 30.0%, 19.6%, 5.9%, respectively,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Multivariable Cox analysis identified low tumor mutational burden (hazard ratio [HR]=2.49, 95% confidence interval [CI]: 1.60\u20133.88,\n                      <jats:italic>P&amp;lt;<\/jats:italic>\n                      0.001), second-or-higher-line immunotherapy (HR = 2.83, 95% CI: 1.81\u20134.44,\n                      <jats:italic>P&amp;lt;<\/jats:italic>\n                      0.001), and high metastatic organ counts (3 organs: HR = 2.21, 95% CI: 1.40\u20133.51,\n                      <jats:italic>P=<\/jats:italic>\n                      0.001; \u22654 organs: HR = 3.85, 95% CI: 2.06\u20137.22,\n                      <jats:italic>P&amp;lt;<\/jats:italic>\n                      0.001) as independent factors associated with low PFS time. Additionally, patients with lung metastasis had a markedly lower ORR (14.6%) than did others (distant lymph node [30.7%], liver [30.3%], peritoneum [29.5%];\n                      <jats:italic>P&amp;lt;<\/jats:italic>\n                      0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increased metastatic organ count in patients with mCRC was associated with decreased immunotherapy ORR and worse prognosis, with a particularly pronounced effect observed in patients with lung metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1679041","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:29:29Z","timestamp":1765261769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic organ count stratifies survival in immunotherapy-treated metastatic colorectal cancer: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Hai-Yan","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Hao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.3390\/jcm9123889","article-title":"Metastatic colorectal cancer. First line therapy for unresectable disease","volume":"9","author":"Aparicio","year":"2020","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: Rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00783-5","article-title":"Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: A retrospective cohort study","volume":"24","author":"Wang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ccell.2024.05.006","article-title":"Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite","volume":"42","author":"Li","year":"2024","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e004884","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.3390\/cancers13246206","article-title":"The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis","volume":"13","author":"Chandra","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"Irecist: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejca.2023.03.029","article-title":"Tumour mutational burden as a biomarker in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"187","author":"Manca","year":"2023","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981527","article-title":"Case report: The msi-l\/p-mmr metastatic rectal cancer patient who failed systemic therapy responds to anti-pd-1 immunotherapy after stereotactic body radiation-therapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000258","article-title":"Clinical correlates of response to anti-pd-1-based therapy in patients with metastatic melanoma","volume":"42","author":"Davis","year":"2019","journal-title":"J Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03271-1","article-title":"Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer","volume":"146","author":"Hakozaki","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the pre-metastatic niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2621","article-title":"The metastatic niche: Adapting the foreign soil","volume":"9","author":"Psaila","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e005345","DOI":"10.1136\/jitc-2022-005345","article-title":"Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice","volume":"10","author":"K\u00fc\u00e7\u00fckk\u00f6se","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cell.2024.03.021","article-title":"A pan-cancer analysis of the microbiome in metastatic cancer","volume":"187","author":"Battaglia","year":"2024","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00821-x","article-title":"The dynamic lung microbiome in health and disease","volume":"21","author":"Natalini","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9464","DOI":"10.1038\/s41467-025-64531-7","article-title":"Tissue localization of natural killer cells dictates surveillance of lung metastasis","volume":"16","author":"Vermeer","year":"2025","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.036","article-title":"Tgf-\u03b2 signaling in health and disease","volume":"186","author":"Massagu\u00e9","year":"2023","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"113437","DOI":"10.1016\/j.ejca.2023.113437","article-title":"Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases","volume":"196","author":"Fakih","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:29:30Z","timestamp":1765261770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1679041"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1679041","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1679041"}}